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Antimicrobial resistance among isolates cultured from 
patients hospitalized with lower respiratory tract infection 
in Europe 
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Lower respiratory tract infections represent a major 
concern, especially with increasing numbers of resistant 
Streptococcus pneumoniae, extended-spectrum p- 
lactamase-producing Enterobacteriaceae, and Staphylo- 
coccus aureus with reduced susceptibility to vanco- 
mycin. Here, we report on the susceptibilities of isolates 
cultured from patients with lower respiratory tract 
infection to different antibiotics obtained from 20 
western and central European hospitals in 1997 and 
1998 as part of the SENTRY Antimicrobial surveillance 
Program.’ 
In total, 2083 isolates were obtained. The most 
frequently isolated organisms from patients with lower 
respiratory tract infection were Staphylococcus aureus 
and Pseudomonas aeruginosa, comprising 21.0% and 
20.3% of the isolates, respectively, followed by Entero- 
batter spp. (7.9%), Escherichia coli (7.0%), Strepto- 
coccus pneumoniae (5.7%), Haemophilus infiuenzae 
(4.7%), Acinetobacter spp. (4.4%), Klebsiella pneu- 
moniae (4.3%), Serratia spp. (3.8%), and Steno- 
trophomonas maltophilia (2.6%).The large contribution 
of Staphylococcus aureus is in agreement with a 1996 
American national nosocomial infection surveillance 
report, which showed that Staphylococcus aureus was 
the commonest cause of pneumonia, accounting for 
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19% of all isolates.2 Comparison of the frequency of 
isolation of bacterial species cultured from patients with 
lower respiratory tract infection in hospitalized patients 
between the European and Latin American arms of 
SENTRY shows that P aeruginosa and Staphylococcus 
aureus are the top two species, although their order is 
reversed.3 Acinetobacter spp. ranked third in Latin 
America, with 11.9%, compared to seventh position in 
Europe. On the other hand, only 1.4% of the isolates 
were Streptococcus pneumoniae in Latin America, 
compared to 5.7% in Europe. Notably, H. influenzae is 
absent among the top 10 species isolated in Latin 
America. 
The MICSOS, MIC9oS and percentage susceptibilities 
of Staphylococcus aureus and Streptococcus pneumoniae 
for various antibiotics are presented in Tables 1 and 2, 
respectively. Intermediate-resistant penicillin-resistant 
isolates were obtained from Germany, France, Spain, 
and Poland. The highly resistant isolates were obtained 
from Germany, France, and Spain. All isolates, with the 
exception of two penicillin-resistant Streptococcus 
pneumoniae isolates from France, were completely 
susceptible to quinupristin-dalfopristin. 
The MI&s, MI&$ and percentage susceptibilities 
of Enterobacteriaceae and other Gram-negative bacteria 
for various antibiotics are presented in Tables 3 and 
4, respectively. H. injkenzae was susceptible to all 
p-lactam and fluoroquinolone antibiotics tested. Based 
on resistance against ceftazidime, ceftriaxone, or 
aztreonam, four (2.7%) E. coli isolates and 13 (14.4%) 
K. pneumoniae isolates carried an extended-spectrum 
P-lactamase or were overproducers of AmpC. 
Resistance to various antibiotics also tended to be 
higher for isolates from southern Europe, and isolates 
from hospitalized patients with lower respiratory infec- 
tion showed markedly higher rates of resistance against 
most antibiotics compared to isolates from community- 
acquired pneumonia.4 In comparison to Gram-negative 
isolates from Latin America, the European isolates 
generally have clearly higher susceptibilities to almost 
all antibiotics tested.” 
With the exception of Acinetobacter spp., the 
susceptibilities of bacterial isolates cultured from 
patients with lower respiratory tract infection to various 
antibiotics still allow adequate treatment with traditional 
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Table 1. Antimicrobial susceptibility (“/OS) and spectrum of activity (MIC so& of different antimicrobial 
agents against 5. aureus isolates obtained from patients with lower respiratory tract infection. 
Antimicrobial agents 
isolates 
MRSA (n=l51)” MSSA (n=289) 
MICso/go %Susc MGo/go %Susc 
wlml w/ml 
Cefazolin >16/>16 0.0 <2/4 100.0 
Ceftriaxone >321>32 0.0 214 100.0 
lmipenem >a/>8 0.0 SO.06lO.25 100.0 
Gentamicin >16/>16 29.8 0.511 95.9 
Ciprofloxacin >2/>2 8.6 0.25/>2 88.2 
Erythromycin >a/>8 6.6 0.5h.a 75.1 
Clindamycin >a/>8 17.9 0.1210.25 91.4 
Quinupristin/dalfopristin 0.510.5 98.0 0.2510.5 99.7 
Doxycycline 4/>4 94.8 ~0.5K0.5 98.6 
Minocyclineb 214 100 SO.25lO.25 98.4 
Rifampin lb2 50.3 10.25KO.25 98.3 
Teicoplanin l/2 100.0 0.511 100.0 
Vancomycin II2 100.0 Ill 100.0 
aMRSA=methicillin-resistant 5. aureus; MSSA=methicillin-sensitive 5. aureus; %umber of MRSA isolates tested 55: 
number of MSSA isolates tested: 127. 
Table 2. Antimicrobial susceptibility (%S) and activity spectrum (MIC 50,~) of different antimicrobial agents against 
Streptococcus pneumoniae obtained from patients with lower respiratory tract infection. 
Antimicrobial agent 
lsola tes 
PS-S. pneumoniae (n=88p PI-S. pneumoniae (n=78) PR-S. pneumoniae (n=lS) 
MICso/go % susc M&o/go %Susc (MGo/go % Susc) 
Mm1 wfml Mm1 
Penicillin 
Cefotaxime 
Cefuroxime 
Levofloxacin 
Grepafloxacin 
Trovafloxacin 
Gatifloxacinb 
Erythromycin 
Clindamycin 
Azithromycin 
Quinupristin/dalfopristin 
Vancomycin 
<0.06/~0.06 
sO.03lO.06 
0.015/0.03 
10.06/0.12 
l/2 
10.1210.25 
0.12/0.5 
0.2510.5 
SO.2510.5 
~0.06K0.06 
10.1210.25 
0.510.5 
0.2510.5 
100.0 
100.0 
100.0 
100.0 
98.9 
100 
100 
- 
88.6 
96.6 
94.3 
100.0 
100.0 
0.5/2 
0.5/l 
0.12/l 
0.514 
l/2 
<0.12/0.25 
0.1210.25 
0.2510.25 
0.5/>32 
0.25ba 
0.5/>16 
0.511 
0.2510.5 
66.7 
0.0 
88.9 
55.6 
100.0 
100.0 
100.0 
- 
44.4 
61.1 
50.0 
100.0 
100.0 
2ba 0.0 
214 0.0 
II2 20.0 
a/a 0.0 
112 100.0 
<0.12/10.12 100.0 
0.2510.5 100.0 
0.25lO.5 - 
>321>32 0.0 
sat>8 13.3 
>16/>16 13.3 
0.512 80.0 
0.510.5 100.0 
aPS=peniciIIin-susceptibie; PI=penicillin-intermediate resistant; PR=penicillin-resistant; %nvestigational drug, no NCCLS breakpoint 
defined. 
Table 3. Antimicrobial susceptibility and spectrum of activity of different antimicrobial agents against the most prevalent 
Enterobacteriaceae cultured from patients with lower respiratory tract infections. 
Antimicrobial agent 
Ampicillin 
Piperacillin 
Amoxicillin/clavulanate 
Piperacillin/tazobactam 
Ceftriaxone 
Ceftazidime 
Cefepime 
Aztreonam 
lmipenem Amikacin 
Gentamicin Tobramycin 
Ciprofloxacin 
Ofloxacin 
Levofloxacin 
E. coli (147) 
M&o/go %Susc 
w/ml 
>16/>16 46.3 
4k-128 53.7 
II16 76.2 
SO.512 95.2 
10.25K0.25 97.7 
<0.12/0.5 97.3 
<0.12/I0.12 98.0 
<0.12/0.25 98.0 
0.25fO.5 100.0 214 
100.0 
l/2 94.6 l/2 93.2 
SO.O15/0.12 93.9 
0.0610.5 93.2 
SO.5ISO.5 93.9 
Isolates 
Enterobacter spp. (167) K. pneumoniae (90) 
M&o/go % susc MICso/go %Susc 
Wml wfml 
>16/>16 34.7 >16/>16 6.7 
2b.128 65.3 16/>128 61.1 
>16/>16 5.4 2116 82.2 
I/64 75.5 l/64 86.7 
<0.25/>32 74.9 SO.25132 85.6 
0.25/>16 74.9 <0.12/>16 85.6 
20.1214 97.1 10.1214 93.3 
<0.12/>16 78.4 <0.12/16 87.8 
0.512 98.8 0.2511 100.0 
218 95.8 218 96.7 
0.512 92.2 0.5/>16 82.2 l/16 8 .0 l/16 0.0 
<0.015/>2 85.6 
0.0310.25 95.6 
0.06/>4 83.8 0.06/l 95.6 
<0.5/>4 86.8 5 0.5K0.5 96.7 
Serratia spp. (79) 
MKso/go %Susc 
wlml 
>16/>16 17.7 
m>i28 81.0 
>16/>16 11.4 
l/32 88.6 
10.25116 89.9 
10.12/l 93.7 
<0.12/0.5 97.5 
SO.1214 93.7 
0.5/2 100.0 
2116 93.7 
0.5/16 83.5 
2/>16 82.3 
0.0612 89.9 
0.2512 93.7 
so.5/1 97.5 
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Table 4. Antimicrobial susceptibility (%S) and activity spectrum (MIC~WVJ) of different antimicrobial agents against 
gram-negative organisms cultured from patients with lower respiratory tract infection. 
Antimicrobial agent 
Piperacillin 
Ticarcillin 
Ticarcillin-clavulanate 
Piperacillin-tazobactam 
Ceftriaxone 
Ceftazidime 
Cefepime 
Aztreonam 
Meropenem 
lmipenem 
Amikacin 
Gentamicin 
Ciprofloxacin 
Ofloxacin 
Levofloxacin 
lsola tes 
P aeruginosa (n=428) Acinetobacter spp. (n=92) 5. maltophilia (n=SS) 
MIGOISQ %SUSC MlCso/so 0% susc MlCso/s0 % SUSC 
Mm1 wJml vuglml 
4/>128 83.2 128/z-128 35.9 64/>128 30.9 
16/>128 80.6 321128 46.7 32h.128 43.6 
161128 83.4 32/>128 49.9 2l64 81.8 
4l>64 88.6 32/>64 48.9 16/>64 52.7 
16/>32 41.8 >321>32 33.7 >32/>32 13.0 
2/>16 82.9 16/>16 46.7 4/>16 70.9 
2/l 6 86.9 al>16 60.9 >16/>16 58.2 
4/>16 77.3 >16/>16 23.9 16l>16 43.6 
0.2518 86.5 1/>8 77.2 S8l>8 9.1 
II>8 79.4 0.5/>8 79.4 >8/>8 0.0 
4116 91.1 16/>32 50.0 16/>32 61.8 
21>16 77.3 >16/>16 34.8 4/>16 50.9 
0.25/>2 78.3 >2>2 38.0 0.51~2 81.8 
II>4 70.1 >4/>4 38.0 0.512 96.4 
<0.5/>4 77.3 4/>4 39.1 SO.511 95.7 
“no NCCLS breakpoint defined; b investigational drug, no NCCLS breakpoints defined 
first-line antibiotics, although the situation with p 
aeruginosa and Staphylococcus aureus gives reason for 
concern. Close monitoring of bacterial isolates for 
resistance will be required. 
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